This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meluch, A. A. Articles by Hainsworth, J. D. Search for Related Content PubMed PubMed Citation Articles by Meluch, A. A. Articles by Hainsworth, J. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Bladder Cancer Hazardous Substances DB TAXOL Social Bookmarking                            What's this?

Paclitaxel and Gemcitabine Chemotherapy for Advanced Transitional-Cell Carcinoma of the Urothelial Tract: A Phase II Trial of the Minnie Pearl Cancer Research Network

From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA.

Address reprint requests to Anthony A. Meluch, MD, The Sarah Cannon Cancer Center, 250 25th Ave North, Ste 412, Nashville, TN 37203; email: ameluch{at}tnonc.com

PURPOSE: To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel and gemcitabine in patients with advanced transitional-cell carcinoma of the urothelial tract.

PATIENTS AND METHODS: Fifty-four patients with advanced unresectable urothelial carcinoma entered this multi-centered, community-based, phase II trial between May 1997 and December 1999. All patients were treated with paclitaxel 200 mg/m² by 1-hour intravenous (IV) infusion on day 1 and gemcitabine 1,000 mg/m² IV on days 1, 8, and 15; courses were repeated every 21 days. Patients who had objective response or stable disease continued treatment for six courses.

RESULTS: Twenty-nine of 54 patients (54%; 95% confidence interval, 40% to 67%) had major responses to treatment, including 7% complete responses. With a median follow-up of 24 months, 16 patients (30%) remain alive and nine (17%) are progression-free. The median survival for the entire group was 14.4 months; 1- and 2-year actuarial survival rates were 57% and 25%, respectively. Seven (47%) of 15 patients previously treated with platinum-based chemotherapy responded to paclitaxel/gemcitabine. Grade 3/4 toxicity was primarily hematologic, including leukopenia (46%), thrombocytopenia (13%), and anemia (28%). Ten patients (19%) required hospitalization for neutropenia and fever, and one patient had treatment-related septic death.

CONCLUSION: The combination of paclitaxel and gemcitabine is active and well tolerated in the first- or second-line treatment of patients with advanced transitional-cell carcinoma of the urothelial tract. Response rate and duration compare favorably with those produced by other active, first-line regimens. This regimen should be further evaluated in phase II and III studies, as well as in patients with compromised renal function.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Sonpavde, A. A. Elfiky, and J. E. Rosenberg Review: Novel agents for advanced bladder cancer Therapeutic Advances in Medical Oncology, July 1, 2009; 1(1): 37 - 50. [Abstract] [PDF]

				T. Suyama, T. Ueda, S. Fukasawa, Y. Imamura, K. Nakamura, K. Miyasaka, T. Sazuka, K.-i. Egoshi, N. Nihei, M. Hamano, et al. Combination of Gemcitabine and Paclitaxel as Second-line Chemotherapy for Advanced Urothelial Carcinoma Jpn. J. Clin. Oncol., April 1, 2009; 39(4): 244 - 250. [Abstract] [Full Text] [PDF]

				C. Sweeney, D. F. Bajorin, and C. N. Sternberg Muscle-invasive Bladder Cancer: What Have We Learned and What's New on the Horizon? ASCO Educational Book, January 1, 2008; 2008(1): 200 - 208. [Abstract] [Full Text] [PDF]

				J Carles, E Esteban, M Climent, A Font, J. Gonzalez-Larriba, A Berrocal, I Garcia-Ribas, X Marfa, X Fabregat, J Albanell, et al. Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer Ann. Onc., August 1, 2007; 18(8): 1359 - 1362. [Abstract] [Full Text] [PDF]

				R Sawhney, D Bourgeois, and U. Chaudhary Neo-adjuvant chemotherapy for muscle-invasive bladder cancer: a look ahead Ann. Onc., September 1, 2006; 17(9): 1360 - 1369. [Abstract] [Full Text] [PDF]

				C. J. Sweeney, B. J. Roth, F. F. Kabbinavar, D. J. Vaughn, M. Arning, R. E. Curiel, C. K. Obasaju, Y. Wang, S. J. Nicol, and D. S. Kaufman Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium J. Clin. Oncol., July 20, 2006; 24(21): 3451 - 3457. [Abstract] [Full Text] [PDF]

				C. Theodore, F. Bidault, N. Bouvet-Forteau, M. Abdelatif, K. Fizazi, M. di Palma, P. Wibault, R. de Crevoisier, and A. Laplanche A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract Ann. Onc., June 1, 2006; 17(6): 990 - 994. [Abstract] [Full Text] [PDF]

				A. Bamias, I. Tiliakos, M.-D. Karali, and M. A. Dimopoulos Systemic chemotherapy in inoperable or metastatic bladder cancer Ann. Onc., April 1, 2006; 17(4): 553 - 561. [Abstract] [Full Text] [PDF]

				T. Takahashi, S. Higashi, H. Nishiyama, T. Segawa, E. Nakamura, H. Kinoshita, N. Itoh, S. Yamamoto, T. Kamoto, T. Habuchi, et al. Biweekly Paclitaxel and Gemcitabine for Patients with Advanced Urothelial Cancer Ineligible for Cisplatin-Based Regimen Jpn. J. Clin. Oncol., February 1, 2006; 36(2): 104 - 108. [Abstract] [Full Text] [PDF]

				M. D. Galsky The Role of Taxanes in the Management of Bladder Cancer Oncologist, November 1, 2005; 10(10): 792 - 798. [Abstract] [Full Text] [PDF]

				J. Li, B. Juliar, C. Yiannoutsos, R. Ansari, E. Fox, M. J. Fisch, L. H. Einhorn, and C. J. Sweeney Weekly Paclitaxel and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium: A Phase II Hoosier Oncology Group Study J. Clin. Oncol., February 20, 2005; 23(6): 1185 - 1191. [Abstract] [Full Text] [PDF]

				L. C. Pagliaro, R. E. Millikan, S.-M. Tu, D. Williams, D. Daliani, C. N. Papandreou, and C. J. Logothetis Cisplatin, Gemcitabine, and Ifosfamide As Weekly Therapy: A Feasibility and Phase II Study of Salvage Treatment for Advanced Transitional-Cell Carcinoma J. Clin. Oncol., July 1, 2002; 20(13): 2965 - 2970. [Abstract] [Full Text] [PDF]